卡培他滨在转移性鼻咽癌维持治疗的疗效观察  

Capecitabine Efficacy of Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma

作　　者：马慧敏[1] 林燕锋[1] 袁霞[1] 

机构地区：[1]惠州市中心人民医院肿瘤内科,广东惠州516000

出　　处：《中国医药指南》2013年第11期3-4,共2页Guide of China Medicine

基　　金：广东省医学科学技术研究基金(项目编号:WSTJ20101221441322197610040229)

摘　　要：目的评价卡培他滨在转移性鼻咽癌维持治疗的近期疗效和毒性反应。方法将我院收治63例转移性鼻咽癌患者在一线姑息化疗4~6个疗程获得CR、PR、SD后随机分为单药卡培他滨维持治疗组和观察组,对比分析两组患者的近期疗效和毒性反应。结果治疗组患者临床疗效明显优于观察组（P〈0.05）,治疗组患者治疗后2年生存率优于观察组（P〈0.05）,治疗组患者不良反应较对照组高,但患者能耐受。结论卡培他滨在转移性鼻咽癌维持治疗中疗效佳,不良反应可耐受,值得临床进一步研究。Objective To evaluate capecitabine in the maintenance treatment of metastatic nasopharyngeal efficacy and toxicity. Method In our hospital, 63 patients with metastatic nasopharyngeal carcinoma patients in the first-line palliative chemotherapy 4-6 cycle with who get CR, PR, SD, were randomly divided into single-agent capecitabine maintain the treatment group and the observation group, analysis of the efficacy and toxicity of the two groups of patients. Results The clinical efficacy of the treatment group was significantly better than the observation group（P〈0.05）, 2-year survival rate of treated patients after treatment is better than the observation group（P〈0.05）. Adverse reactions in patients of the treatment group compared with the control group, but the patient can tolerate. Conclusion Capecitabine in the metastatic nasopharyngeal maintaining good efficacy in the treatment, adverse reactions may be tolerated, and is worthy of further study.

关 键 词：卡培他滨 转移性鼻咽癌 维持治疗 

分 类 号：R739.63[医药卫生—肿瘤]